280 related articles for article (PubMed ID: 31427010)
21. Redox-responsive polymer-drug conjugates based on doxorubicin and chitosan oligosaccharide-g-stearic acid for cancer therapy.
Su Y; Hu Y; Du Y; Huang X; He J; You J; Yuan H; Hu F
Mol Pharm; 2015 Apr; 12(4):1193-202. PubMed ID: 25751168
[TBL] [Abstract][Full Text] [Related]
22. Synergistic effect of quercetin and pH-responsive DEAE-chitosan carriers as drug delivery system for breast cancer treatment.
de Oliveira Pedro R; Goycoolea FM; Pereira S; Schmitt CC; Neumann MG
Int J Biol Macromol; 2018 Jan; 106():579-586. PubMed ID: 28807690
[TBL] [Abstract][Full Text] [Related]
23. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
24. Preparation of pH-sensitive chitosan/polyvinylpyrrolidone/α-Fe
Gerami SE; Pourmadadi M; Fatoorehchi H; Yazdian F; Rashedi H; Nigjeh MN
Int J Biol Macromol; 2021 Mar; 173():409-420. PubMed ID: 33454326
[TBL] [Abstract][Full Text] [Related]
25. Chemosensitizing indomethacin-conjugated chitosan oligosaccharide nanoparticles for tumor-targeted drug delivery.
Lee JY; Termsarasab U; Lee MY; Kim DH; Lee SY; Kim JS; Cho HJ; Kim DD
Acta Biomater; 2017 Jul; 57():262-273. PubMed ID: 28483700
[TBL] [Abstract][Full Text] [Related]
26. Natural gelatin capped mesoporous silica nanoparticles for intracellular acid-triggered drug delivery.
Zou Z; He D; He X; Wang K; Yang X; Qing Z; Zhou Q
Langmuir; 2013 Oct; 29(41):12804-10. PubMed ID: 24073830
[TBL] [Abstract][Full Text] [Related]
27. Chitosan-g-TPGS nanoparticles for anticancer drug delivery and overcoming multidrug resistance.
Guo Y; Chu M; Tan S; Zhao S; Liu H; Otieno BO; Yang X; Xu C; Zhang Z
Mol Pharm; 2014 Jan; 11(1):59-70. PubMed ID: 24229050
[TBL] [Abstract][Full Text] [Related]
28. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance.
Wang J; Sun J; Chen Q; Gao Y; Li L; Li H; Leng D; Wang Y; Sun Y; Jing Y; Wang S; He Z
Biomaterials; 2012 Oct; 33(28):6877-88. PubMed ID: 22770799
[TBL] [Abstract][Full Text] [Related]
29. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors.
Butt AM; Amin MC; Katas H; Abdul Murad NA; Jamal R; Kesharwani P
Mol Pharm; 2016 Dec; 13(12):4179-4190. PubMed ID: 27934479
[TBL] [Abstract][Full Text] [Related]
30. Photo- and pH-Responsive Polycarbonate Block Copolymer Prodrug Nanomicelles for Controlled Release of Doxorubicin.
Kalva N; Uthaman S; Augustine R; Jeon SH; Huh KM; Park IK; Kim I
Macromol Biosci; 2020 Aug; 20(8):e2000118. PubMed ID: 32567108
[TBL] [Abstract][Full Text] [Related]
31. PEGylated and poloxamer-modified chitosan nanoparticles incorporating a lysine-based surfactant for pH-triggered doxorubicin release.
Scheeren LE; Nogueira DR; Macedo LB; Vinardell MP; Mitjans M; Infante MR; Rolim CM
Colloids Surf B Biointerfaces; 2016 Feb; 138():117-27. PubMed ID: 26674840
[TBL] [Abstract][Full Text] [Related]
32. Preparation of polysaccharide derivates chitosan-graft-poly(ɛ-caprolactone) amphiphilic copolymer micelles for 5-fluorouracil drug delivery.
Gu C; Le V; Lang M; Liu J
Colloids Surf B Biointerfaces; 2014 Apr; 116():745-50. PubMed ID: 24529474
[TBL] [Abstract][Full Text] [Related]
33. Development of chitosan/halloysite/graphitic‑carbon nitride nanovehicle for targeted delivery of quercetin to enhance its limitation in cancer therapy: An in vitro cytotoxicity against MCF-7 cells.
Sabzini M; Pourmadadi M; Yazdian F; Khadiv-Parsi P; Rashedi H
Int J Biol Macromol; 2023 Jan; 226():159-171. PubMed ID: 36435458
[TBL] [Abstract][Full Text] [Related]
34. A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy.
Xiong S; Wang Z; Liu J; Deng X; Xiong R; Cao X; Xie Z; Lei X; Chen Y; Tang G
Colloids Surf B Biointerfaces; 2019 Jan; 173():346-355. PubMed ID: 30316081
[TBL] [Abstract][Full Text] [Related]
35. Design and evaluation of galactosylated chitosan/graphene oxide nanoparticles as a drug delivery system.
Wang C; Zhang Z; Chen B; Gu L; Li Y; Yu S
J Colloid Interface Sci; 2018 Apr; 516():332-341. PubMed ID: 29408121
[TBL] [Abstract][Full Text] [Related]
36. Comb-like amphiphilic copolymers bearing acetal-functionalized backbones with the ability of acid-triggered hydrophobic-to-hydrophilic transition as effective nanocarriers for intracellular release of curcumin.
Zhao J; Wang H; Liu J; Deng L; Liu J; Dong A; Zhang J
Biomacromolecules; 2013 Nov; 14(11):3973-84. PubMed ID: 24107101
[TBL] [Abstract][Full Text] [Related]
37. Chitosan-capped mesoporous silica nanoparticles as pH-responsive nanocarriers for controlled drug release.
Hu X; Wang Y; Peng B
Chem Asian J; 2014 Jan; 9(1):319-27. PubMed ID: 24115568
[TBL] [Abstract][Full Text] [Related]
38. Co-delivery of doxorubicin and interleukin-2 via chitosan based nanoparticles for enhanced antitumor efficacy.
Wu J; Tang C; Yin C
Acta Biomater; 2017 Jan; 47():81-90. PubMed ID: 27729232
[TBL] [Abstract][Full Text] [Related]
39. Chitosan-based DDSs for pH/hypoxia dual-triggered DOX delivery: Facile morphology modulation for higher in vitro cytotoxicity.
Xie P; Liu P
Carbohydr Polym; 2022 Jan; 275():118760. PubMed ID: 34742449
[TBL] [Abstract][Full Text] [Related]
40. TNYL peptide functional chitosan-g-stearate conjugate micelles for tumor specific targeting.
Chen FY; Yan JJ; Yi HX; Hu FQ; Du YZ; Yuan H; You J; Zhao MD
Int J Nanomedicine; 2014; 9():4597-608. PubMed ID: 25298734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
